April 28, 2021

Biogen Provides Regulatory Update on the Supplemental Biologic License Application (sBLA) for Subcutaneous Administration of TYSABRI® (natalizumab)

CAMBRIDGE, Mass., April 28, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for its supplemental Biologic License Application (sBLA) for a new subcutaneous (SC) route of

October 21, 2019

Biogen and Samsung Bioepis to Present Data for Infliximab and Adalimumab Biosimilars at United European Gastroenterology Week

Data highlight s real-world evidence confirming the safety and efficacy of anti-TNF biosimilars for patients with i nflammatory b owel d isease (IBD) CAMBRIDGE, Mass. and INCHEON, Korea, Oct. 21, 2019 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Samsung Bioepis today announced that they will

October 2, 2019

Landmark NURTURE Study of Infants with Spinal Muscular Atrophy (SMA) Treated Pre-Symptomatically with SPINRAZA® (nusinersen) Published in Neuromuscular Disorders

Treatment with SPINRAZA resulted in survival of 100 percent of infants, with none requiring permanent ventilation Motor milestones achieved included 100 percent of participants sitting without support and 88 percent walking independently; unprecedented outcomes in comparison to the natural history

October 1, 2019

Biogen Announces Leadership Update

Dr. Alfred Sandrock is named Executive Vice President, Research and Development and continues as Chief Medical Officer Dr. Alphonse Galdes appointed Executive Vice President, Pharmaceutical Operations and Technology Dr. Michael Ehlers, Executive Vice President, Research and Development has decided

September 23, 2019

Interferon Beta Treatments, Including PLEGRIDY® (peginterferon beta-1a) and AVONEX® (interferon beta-1a), Receive Positive CHMP Opinion for Use During Pregnancy and Breastfeeding

Positive opinion is supported by data from more than 1,000 real-world pregnancy outcomes Data indicate no increased risk of major congenital anomalies after exposure to interferon beta before conception and/or during first trimester Data show pregnancy outcomes are in line with general population

September 18, 2019

Biogen Advances Spinal Muscular Atrophy (SMA) Clinical Research with New Study Evaluating a Higher Dose of SPINRAZA® (nusinersen) and Additional Data in a Broad Range of Patients

DEVOTE trial to evaluate safety and even greater efficacy of a higher dose of SPINRAZA in the treatment of SMA; well-established safety profile supports exploration of potential benefits Long-term data from the SHINE study demonstrate improvements in or stabilization of motor function in patients

September 17, 2019

Biogen Ranked #1 Biotechnology Company on Dow Jones Sustainability World Index

CAMBRIDGE, Mass., Sept. 17, 2019 (GLOBE NEWSWIRE) -- Biogen Inc.  (Nasdaq: BIIB) today announced that it has been ranked the #1 biotechnology company on the Dow Jones Sustainability World Index (DJSI World) for the fourth time, after being the first U.S.-based biotech company to ever make the list

September 12, 2019

New Research Demonstrate Biogen’s Continued Commitment to Improve Care of Patients with Multiple Sclerosis Across Treatment Spectrum

Data highlight benefits of TYSABRI ® (natalizumab) treatment in early multiple sclerosis for achieving NEDA (no evidence of disease activity) and improving disability and cognition An analysis of data from the TYSABRI Observational Program (TOP) demonstrates real-world effectiveness of extended

September 11, 2019

Biogen to Report Third Quarter 2019 Financials October 22,2019

Cambridge, Mass.— Biogen Inc . (Nasdaq:BIIB) today announced it will report third quarter 2019 financial results Tuesday, October 22, 2019, before the financial markets open. Following the release of the financials, the Company will host a live webcast with Biogen management from 8:00-9:00 am ET.

September 11, 2019

New Data Presented at ECTRIMS Reinforce Long-term Benefits of TECFIDERA® (dimethyl fumarate) Over 10 Years

TECFIDERA consistently maintained low levels of disease activity with no increased risk in adverse events over a decade of treatment Latest interim data from Phase 3 EVOLVE-MS-1 trial show Biogen and Alkermes’ investigational treatment, diroximel fumarate, was generally well tolerated with low

July 30, 2019

Diroximel Fumarate Demonstrated Significantly Improved Gastrointestinal Tolerability Profile Compared to Dimethyl Fumarate in Patients with Multiple Sclerosis

— Diroximel Fumarate Demonstrated Statistically Superior Gastrointestinal (GI) Tolerability on EVOLVE-MS-2 Study’s Primary Endpoint Assessing Self-Reported GI Events — — Discontinuations Due to GI Events were Less than 1% for Diroximel Fumarate — DUBLIN, Ireland and CAMBRIDGE, Mass., July 30, 2019